For research use only. Not for therapeutic Use.
Deucravacitinib（Cat No.:I019790）is an oral, selective tyrosine kinase 2 (TYK2) inhibitor used for the treatment of moderate to severe plaque psoriasis. By targeting TYK2, a key enzyme in the JAK-STAT signaling pathway, Deucravacitinib blocks the activity of cytokines involved in inflammation and immune response, such as IL-23 and IL-12. Its specificity for TYK2 minimizes the potential for off-target effects, offering a favorable safety profile compared to broader JAK inhibitors. Deucravacitinib provides a novel therapeutic option for patients seeking effective, long-term management of psoriasis with improved tolerability.
| Catalog Number | I019790 |
| CAS Number | 1609392-27-9 |
| Synonyms | 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide |
| Molecular Formula | C20H19D3N8O3 |
| Purity | 99% |
| Target | TYK2 |
| Target Protein | |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IC50 | Tyk2 JH2：0.2 nM (IC50) |
| IUPAC Name | 6-(cyclopropanecarbonylamino)-4-[2-methoxy-3-(1-methyl-1,2,4-triazol-3-yl)anilino]-N-(trideuteriomethyl)pyridazine-3-carboxamide |
| InChI | InChI=1S/C20H22N8O3/c1-21-20(30)16-14(9-15(25-26-16)24-19(29)11-7-8-11)23-13-6-4-5-12(17(13)31-3)18-22-10-28(2)27-18/h4-6,9-11H,7-8H2,1-3H3,(H,21,30)(H2,23,24,25,29)/i1D3 |
| InChIKey | BZZKEPGENYLQSC-FIBGUPNXSA-N |
| SMILES | [2H]C([2H])([2H])NC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 |
| Reference | [1]. Wrobleski ST, et al. Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165. J Med Chem. 2019 Jul 18. [2]. Catlett I, et al. SAT0226 A first-in-human, study of BMS-986165, a selective, potent, allosteric small molecule inhibitor of tyrosine kinase 2. Annals of the Rheumatic Diseases 2017;76:859. |
